LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Search

Teva Pharmaceutical Industries Ltd.

Chiusa

SettoreSettore sanitario

34.29 -2.83

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

34.15

Massimo

34.53

Metriche Chiave

By Trading Economics

Entrata

-112M

369M

Vendite

-730M

4B

P/E

Media del settore

26.746

51.415

EPS

0.53

Margine di Profitto

9.269

Dipendenti

31,173

EBITDA

245M

877M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+23.59% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

5.3B

42B

Apertura precedente

37.12

Chiusura precedente

34.29

Notizie sul Sentiment di mercato

By Acuity

50%

50%

136 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Teva Pharmaceutical Industries Ltd. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 ott 2025, 09:10 UTC

Azioni calde

Stocks to Watch Thursday: HSBC, PepsiCo, MP Materials -- WSJ

Confronto tra pari

Modifica del prezzo

Teva Pharmaceutical Industries Ltd. Previsione

Obiettivo di Prezzo

By TipRanks

23.59% in crescita

Previsioni per 12 mesi

Media 42.38 USD  23.59%

Alto 50 USD

Basso 40 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Teva Pharmaceutical Industries Ltd. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

8

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

15.58 / N/ASupporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

136 / 345 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
help-icon Live chat